Cargando…
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective
Over the last decades, billions have been spent and huge efforts have been taken in basic and clinical cancer research [CA Cancer J Clin 63: 11-30]. About a decade ago, the arms race between drugs and cancer cells reached a new level by introduction of tyrosine kinase inhibitors (TKI) into pharmacol...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922331/ https://www.ncbi.nlm.nih.gov/pubmed/24502453 http://dx.doi.org/10.1186/1756-9966-33-15 |